Cavernous Transformation of Portal Vein： Etiology, Diagnosis, Management and Prognosis

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02505113

Enrollment

150

Registered

2015-07-22

Start date

2010-10-31

Completion date

Unknown

Last updated

2015-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Portal Vein, Cavernous Transformation Of

Keywords

Portal Vein, Cavernous Transformation Of, Hypertension, Portal

Brief summary

To observe the etiology, diagnosis, management and prognosis of cavernous transformation of portal vein.

Detailed description

To observe the etiology, diagnosis, management and prognosis of cavernous transformation of portal vein. We perform Montelukast (10mg, q.d., p.o.) fot the treatment of symptomatic cavernous transformation of portal vein and to observe the efficacy such as the decrease of the volume of ascites and hydrothorax.

Interventions

DRUGMontelukast

Montelukast (10mg, q.d., p.o.)

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Years to 80 Years

Healthy volunteers

Inclusion criteria

* All patients with CTPV.

Exclusion criteria

* Patients with known severe dysfunction of heart, lung, brain, kidney and other vital organs.

Design outcomes

Primary

Measure	Time frame	Description
Ascites Volume (mL)	6 month	Ascites measured by CT scanning or ultrasound (If the patients had the history of ascites before)
Hydrothorax Volume (mL)	6 month	Hydrothorax measured by CT scanning or ultrasound (If the patients had the history of hydrothorax before)

Countries

China

Contacts

Primary ContactZaibo Jiang, MD

jiangzaibo@aliyun.com+86 020 85253416

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026